Retroperitoneal Schwannoma with a Novel PRCC::TFE3 Fusion: Expanding the Spectrum of Schwannomas with a TFE3 Gene Rearrangement.

Int J Surg PatholMay 6, 2026 (epub)

Kyle D Perry, Rohit Mehra, Ann Leathersich et al.

✦ AI-curated · Sources linked

Case in brief

A patient presented with a large retroperitoneal schwannoma characterized by a PRCC::TFE3 fusion. Histological examination revealed large epithelioid cells with granular cytoplasm, alongside degenerative features typical of schwannomas. The tumor was confirmed to be of Schwann cell differentiation through methylation profiling. After complete surgical resection, the patient has had no recurrence.

What made this case unusual

The presence of a PRCC::TFE3 fusion in a schwannoma is noteworthy, as this fusion is typically associated with more aggressive neoplasms like renal cell carcinoma.

Diagnostic / clinical pearl

Clinicians should be aware that schwannomas can exhibit atypical fusions, such as PRCC::TFE3, which may lead to misdiagnosis as more aggressive tumors.

Why it matters

Recognizing this rare schwannoma subtype is crucial for accurate diagnosis and management, preventing potential misclassification with aggressive neoplasms.

Source

Published in Int J Surg Pathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pathology (Anatomic & Clinical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.